<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01909245</url>
  </required_header>
  <id_info>
    <org_study_id>12446</org_study_id>
    <nct_id>NCT01909245</nct_id>
  </id_info>
  <brief_title>Islet Cell Transplant for Type 1 Diabetes</brief_title>
  <acronym>TCD</acronym>
  <official_title>Islet Transplantation Using a T-Cell Depleting Immunosuppression Induction Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      City of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on&#xD;
      islet cell transplantation, an experimental procedure being evaluated as a treatment for&#xD;
      patients with type 1 diabetes. Islet cell transplantation involves taking insulin-producing&#xD;
      cells from organ donors and transplanting them into the liver of a patient with diabetes.&#xD;
      Once transplanted, the islets produce insulin, which can improve blood sugar control and&#xD;
      eliminate the need to inject insulin or use an insulin pump.&#xD;
&#xD;
      Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that&#xD;
      work by decreasing a patient's T-cells. T-cells are special white blood cells that recognize&#xD;
      and destroy unwanted things like infections but can also attack transplanted cells and&#xD;
      organs. Reducing the number of T-cells at the time of transplant may protect islets and&#xD;
      improve long-term transplant success. In previous research studies, islet transplantation has&#xD;
      been successful in reducing low blood sugar episodes, improving overall blood sugar control,&#xD;
      and in some cases, allowing patients with type 1 diabetes to stop taking insulin.&#xD;
&#xD;
      The purpose of this study is to determine if islet cell transplantation using ATG or&#xD;
      alemtuzumab, along with additional medications to prevent the body from rejecting the&#xD;
      transplanted cells, is a safe and effective treatment for type 1 diabetes. Study participants&#xD;
      may receive up to three islet transplants and will be followed for five years to monitor&#xD;
      blood sugar control, islet transplant function, and changes in quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2013</start_date>
  <completion_date type="Anticipated">July 16, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c &lt; or = 6.5% at 1 year post-transplant</measure>
    <time_frame>1 year post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c &lt; or = 6.5% at 2 years post-transplant</measure>
    <time_frame>2 years post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c &lt; or = 6.5% at 5 years post-transplant</measure>
    <time_frame>5 years post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c &lt; or = 7.0%</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of subjects experiencing reduction/elimination of hypoglycemic episodes</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Duration of insulin independence</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who maintain a positive c-peptide secretion response to glucose/glucagon stimulation</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in average daily insulin use compared to baseline</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Decline in insulin intake/100,000 IEQ infused</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Insulin secretion during Intravenous Glucose Tolerance Test (IVGTT), IVGTT+arginine stimulation (IVGTT+AST), Maximum Stimulated Insulin Secretion test (MSIS), and/or Mixed Meal Tolerance Test (MMTT)</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of alloimmune rejection</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rate of autoimmune reactivation</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of adverse events related to islet transplant procedure</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence and severity of adverse events related to immunosuppression</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of change in immunosuppression drug regimen</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of immune sensitization defined by presence of anti-HLA antibodies post-transplant that were absent pre-transplant</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of discontinuation of immunosuppression</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in glucose time within range during continuous glucose monitoring</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Gastrin-17 use for treatment of islet graft dysfunction AND incidence of change or early discontinuation of Gastrin-17 treatment</measure>
    <time_frame>+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Single Arm Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogenic Human Islet Cell Transplant with immunosuppression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogenic Human Islet Cells</intervention_name>
    <description>Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.</description>
    <arm_group_label>Single Arm Study</arm_group_label>
    <other_name>Islet transplant, islet transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunosuppressive Agents</intervention_name>
    <description>Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.</description>
    <arm_group_label>Single Arm Study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gastrin 17</intervention_name>
    <description>Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).</description>
    <arm_group_label>Single Arm Study</arm_group_label>
    <other_name>GAST-17</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Three different categories of patients with Type 1 Diabetes will be considered for study&#xD;
        participation:&#xD;
&#xD;
          -  Naïve islet transplant alone (nITA) candidates: T1D patients complicated by&#xD;
             frequent/severe hypoglycemia, hypoglycemia unawareness, AND/OR otherwise unstable&#xD;
             blood glucose control who have not received a previous transplant (except for a failed&#xD;
             pancreas more than 6 months prior to screening)&#xD;
&#xD;
          -  Repeat transplant (RT) candidates: T1D patients who have received two or fewer&#xD;
             previous islet transplants &gt; 1 month prior to screening, but continue to require&#xD;
             exogenous insulin treatment or have an HbA1c &gt; 6.5%&#xD;
&#xD;
          -  Islet after kidney transplant (IAK) candidates: T1D patients with a history of&#xD;
             successful renal transplant &gt; 3 months prior to screening&#xD;
&#xD;
        Inclusion criteria for all candidates:&#xD;
&#xD;
          1. Age 18-68 years&#xD;
&#xD;
          2. Type 1 diabetes mellitus for at least 5 years&#xD;
&#xD;
          3. Ability and willingness to comply with post-transplant regimen, including taking&#xD;
             anti-rejection medications, use of reliable contraception, frequent clinic visits, lab&#xD;
             tests, careful recording of blood glucose values, insulin doses and medications, and&#xD;
             completing detailed follow-up studies&#xD;
&#xD;
             Additional Inclusion Criteria nITA Candidates Only&#xD;
&#xD;
          4. Unstable blood sugar control characterized by:&#xD;
&#xD;
             Frequent hypoglycemia (blood glucose ≤ 54 mg/dl more than once per week) -AND/OR-&#xD;
             Hypoglycemia unawareness (Clarke score of 4 or more) -AND/OR- One or more severe&#xD;
             hypoglycemic episodes in 12 months preceding enrollment. -AND/OR- Erratic blood&#xD;
             glucose levels that interfere with daily activities -AND/OR- One or more hospital&#xD;
             visits for diabetic ketoacidosis in the 12 months preceding enrollment&#xD;
&#xD;
             Additional Inclusion Criteria for RT Candidates Only&#xD;
&#xD;
          5. One or two or previous islet transplants &gt; 1 month prior to screening with continuing&#xD;
             insulin requirements and/or HbA1c &gt; 6.5%&#xD;
&#xD;
             Additional Inclusion Criteria for IAK Candidates Only&#xD;
&#xD;
          6. Successful kidney transplant &gt; 3 months prior to screening&#xD;
&#xD;
          7. Stable maintenance immunosuppression consisting of tacrolimus alone or in conjunction&#xD;
             with sirolimus, mycophenolate mofetil, myfortic or azathoprine; or cyclosporine in&#xD;
             conjunction with sirolimus, mycophenolate mofetil, or myfortic +/- ≤ 10 mg/day&#xD;
             corticosteroids&#xD;
&#xD;
          8. No history of acute rejection related to kidney graft in last 12 months and low risk&#xD;
             of rejection&#xD;
&#xD;
          9. Under continuing care of physician for kidney graft, who has provided letter in&#xD;
             support of candidate's consideration for study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index (BMI) &gt; 33&#xD;
&#xD;
          2. Insulin requirements &gt; 1.2 units/kg/day&#xD;
&#xD;
          3. Known sensitization to both rATG -and- alemtuzumab&#xD;
&#xD;
          4. Significant kidney dysfunction&#xD;
&#xD;
          5. Significant liver/gall bladder disease&#xD;
&#xD;
          6. Significant cardiovascular disease&#xD;
&#xD;
          7. Active proliferative retinopathy&#xD;
&#xD;
          8. High blood pressure despite appropriate treatment&#xD;
&#xD;
          9. High cholesterol/triglycerides despite appropriate treatment&#xD;
&#xD;
         10. Anemia or other blood disorders that require medical treatment&#xD;
&#xD;
         11. WBC &lt;3,000/ul&#xD;
&#xD;
         12. Increased risk of bleeding, other chronic hemostasis disorders, or treatment with&#xD;
             chronic anticoagulant therapy&#xD;
&#xD;
         13. Recent unresolved acute infection (except for mild skin infection or nail fungal&#xD;
             infection), or chronic infection&#xD;
&#xD;
         14. Epstein-Barr Virus (EBV) IgG negative&#xD;
&#xD;
         15. Any history of malignancy, except for completely resected squamous or basal cell&#xD;
             carcinoma of the skin or in situ cancer of the cervix&#xD;
&#xD;
         16. Recent history of non-adherence to medical treatment, or inability to demonstrate&#xD;
             capacity to comply with strict blood glycemic control and insulin therapy&#xD;
&#xD;
         17. Psychiatric illness that is untreated, or likely to interfere significantly with study&#xD;
             compliance despite treatment&#xD;
&#xD;
         18. Previous organ/tissue transplant, except as noted above&#xD;
&#xD;
         19. Administration of live attenuated vaccines within 2 months of enrollment&#xD;
&#xD;
         20. Presence of a chronic disease that must be chronically treated with a contraindicated&#xD;
             agent&#xD;
&#xD;
         21. Use of investigational agents within four weeks of enrollment&#xD;
&#xD;
         22. Active alcohol or substance abuse, including cigarette smoking&#xD;
&#xD;
         23. Pregnant women, women intending future pregnancy, women of reproductive potential who&#xD;
             are unable or unwilling to follow effective contraceptive measures prior to study&#xD;
             entry and for as long as they are on immunosuppression medication, and women presently&#xD;
             breast feeding are excluded&#xD;
&#xD;
         24. Individuals without health insurance&#xD;
&#xD;
         25. History of gastric bypass&#xD;
&#xD;
         26. Any medical condition that in the opinion of the investigator will interfere with safe&#xD;
             participation in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fouad Kandeel, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Islet Cell Transplant Program</last_name>
    <phone>1-866-44-ISLET (1-866-444-7538</phone>
    <email>islets@coh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Islet Cell Transplant Program</last_name>
      <phone>866-444-7538</phone>
      <email>islets@coh.org</email>
    </contact>
    <investigator>
      <last_name>Fouad Kandeel, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cityofhope.org/islets</url>
    <description>City of Hope Islet Cell Transplantation Program</description>
  </link>
  <results_reference>
    <citation>Aslamy A, Oh E, Ahn M, Moin ASM, Chang M, Duncan M, Hacker-Stratton J, El-Shahawy M, Kandeel F, DiMeglio LA, Thurmond DC. Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab. 2018 May 1;103(5):1966-1976. doi: 10.1210/jc.2017-02492.</citation>
    <PMID>29506054</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 22, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2013</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Islet cells</keyword>
  <keyword>hypoglycemia</keyword>
  <keyword>hypoglycemia unawareness</keyword>
  <keyword>islet after kidney transplantation</keyword>
  <keyword>islet transplant</keyword>
  <keyword>insulin independence</keyword>
  <keyword>insulin dependence</keyword>
  <keyword>labile diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Gastrins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

